<DOC>
	<DOCNO>NCT02859402</DOCNO>
	<brief_summary>Relapsed refractory T-cell lymphoma report dismal outcome . The role allogeneic stem cell transplantation demonstrate patient . This clinical trial study efficacy safety busulfan plus fludarabine conditioning therapy follow allogeneic stem cell transplantation ( Allo-SCT ) T- NK/T-cell lymphoma patient relapse refractory previous chemotherapy include autologous transplantation .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Relapsed/Refractory T- , NK/T-cell Lymphomas</brief_title>
	<detailed_description>Conditioning therapy - Busulfan ( Busulfex® ; Patheon Manufacturing Services LLC , Greenville , NC 27834 ) 3.2 mg/kg + 5 % DW ( diluent quantity 10 time volume Busulfan , final concentration busulfan become approximately 0.5 mg/mL ) , intravenously 3 hour daily 3 day ( day -7 -5 ) - Fludarabine ( Fludarabine® , Zydus Hospira Oncology Private Ltd. , Ahmedabad , India ) 30 mg/m2 + 5 % DW 100㎖ , intravenously 1 hour daily 6 day ( day -8 -3 ) - Busulfan infused soon completion fludarabine infusion Primary objective study I . To determine 2-year progression-free survival reduce toxicity conditioning relapse refractory T- NK/T-cell non-hodgkin lymphoma patient . Secondary endpoint I . To evaluate response rate , engraftment rate time engraftment , 2-year overall survival , 100-days treatment-related mortality , regimen-related toxicity CTCAE version 4.03 , post-transplantation complication ( HVOD , acute/chronic graft-versus-host disease ( GVHD ) , cytomegalovirus ( CMV ) infection , CMV disease ) reduce toxicity conditioning relapse refractory T- NK/T-cell non-hodgkin lymphoma patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Age 19 65 2 . Histologically confirm T NK cell lymphoma : anaplastic large cell lymphoma angioimmunoblastic Tcell lymphoma , peripheral Tcell lymphoma , NOS NK/Tcell lymphoma 3 . Relapsed refractory one previous chemotherapy include frontline autologous HSCT . 4 . At least one measure lesion use conventional CT PET CT time relapse refractory one previous chemotherapy salvage chemotherapy 5 . Complete Partial response short cycle salvage chemotherapy 6 . Patients HLA fullmatch ( 8/8 HLAA , B , C , DR DNA highresolution technique ) onelocus mismatch ( 7/8 ) sibling , unrelated bone marrow peripheral blood cord blood stem cell donor 7 . ECOG performance status ≤ 2 8 . Charlson Comorbidity Index ( CCI ) HSCT &lt; 3 9 . Adequate renal function : serum creatinine level &lt; 2.0 mg/dL 10 . Adequate liver function : Transaminase ( AST/ALT ) &lt; 3 X upper normal value ( &lt; 5 x ULN presence lymphoma involvement liver ) Total bilirubin &lt; 2 X upper normal value ( &lt; 5 x ULN presence NK/T involvement liver ) 11 . Cardiac ejection fraction ≥ 50 % measure MUGA 2D ECHO without clinically significant abnormality 12 . No clinically significant infection 13 . No clinically significant bleeding symptom sign 14 . Patients decide participate study sign write consent 1 . Adult T cell leukemia/lymphoma , Lymphoblastic lymphoma , Primary cutaneous CD30+ T cell disorder Mycosis fungoides , Sezary SD 2 . Patients previously perform AlloHSCT 3 . T cell lymphoma primary central nervous system ( CNS ) Involvement . ** However , patient prophylactic intrathecal intravenous chemotherapy CNS disease eligible . 4 . Patients known history HIV seropositivity HCV ( + ) . ** Patients HBV eligible . However , primary prophylaxis use antiviral agent recommend HBV carrier prevent HBV reactivation whole treatment period . 5 . Any malignancy within past 5 year ** Except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 6 . Ejection fraction &lt; 50 % echocardiography 7 . FEV1 &lt; 60 % DLCO &lt; 60 % pulmonary function test 8 . ECOG performance status 3 4 9 . Combined serious medical problem disease Serious unstable heart disease although proper treatment Myocardial infarction recent 3 month Underlying serious neurologic psychiatric disease include dementia seizure Active uncontrolled infection include hepatitis B C Serious medical problem observe doctor charge patient 10 . Pregnant lactate woman , woman childbearing potential employ adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>T-cell Non-Hodgkin Lymphoma</keyword>
	<keyword>NK/T-cell Non-Hodgkin Lymphoma</keyword>
	<keyword>Relapsed , refractory</keyword>
	<keyword>Conditioning</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
</DOC>